

NEWS & VIEWS REFERENCES

The psychological impact: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
<https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert>

ACE Inhibitors, Angiotensin Receptor Blockers & COVID-19: BMJ Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients
<https://www.medrxiv.org/content/10.1101/2020.03.20.20039586v1>

GDM antenatal and postnatal testing advice to reduce the risk of COVID-19:
<https://www.diabetesaustralia.com.au/covid-19-updates-for-health-professionals>

Living Evidence & COVID-19: <https://covid19evidence.net.au/>

Proactive contact by GPs needed: <https://www.ausdoc.com.au/news/diabetes-tests-ordered-gps-down-75-pathology-crash>

FEATURE REFERENCES

p 10-14 Bone Fragility Fracture: A diabetes complication

1. Magliano, DJ, Barr, ELM, Zimmet, PZ, Cameron, AJ, Dunstan, DW, Colagiuri, S, Jolley, D, Owen, N, Phillips, P, Tapp, RJ, Welborn, TA and Shaw, JE. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care*, 2008. 31(2):267-72.
2. Abimanyi-Ochom, J, Watts JJ, Borgström F, Nicholson GC, Shore-Lorenti C, Stuart AL, Zhang Y, Iuliano S, Seeman E, Prince R, March L, Cross M, Winzenberg T, Laslett LL, Duque G, Ebeling PR, Sanders KM. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). *Osteoporos Int*, 2015. 26(6):1781-90.
3. Lindstrom J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). *Diabetologia*, 2013. 56(2):284-93.
4. Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O'Malley CD. Estimating prevalence of osteoporosis: examples from industrialized countries. *Arch Osteoporos*, 2014. 9:182.
5. Henry MJ, Pasco JA, Nicholson GC, Kotowicz MA, Prevalence of osteoporosis in Australian men and women: Geelong Osteoporosis Study. *Med J Aust*, 2011. 195(6):321-2.
6. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. *Osteoporos Int*, 2016. 27(1):219-28.
7. Weber, DR, Haynes, K, Leonard, MB, Willi, SM, Denburg MR. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). *Diabetes Care*, 2015. 38(10):1913-20.
8. Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgström F, Nicholson GC, Shore-Lorenti C, Stuart AL, Iuliano-Burns S, Seeman E, Prince R, March L, Cross M, Winzenberg T, Laslett LL, Duque G, Ebeling PR, Sanders KM. The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. *J Bone Miner Res*, 2019. 34(4):616-625.
9. Giangregorio, LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. FRAX underestimates fracture risk in patients with diabetes. *J Bone Miner Res*, 2012. 27(2):301-8.
10. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM; Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. *Jama*, 2011. 305(21):2184-92.
11. Hough FS, Pierroz DD, Cooper C, Ferrari SL and The IOF CSA Bone and Diabetes Working Group. MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. *Eur J Endocrinol*, 2016. 174(4):R127-38.

p 10-14 Bone Fragility Fracture Cont'd

12. Roggen I, Gies I, Vanbesien J, Louis O, De Schepper J. Trabecular bone mineral density and bone geometry of the distal radius at completion of pubertal growth in childhood type 1 diabetes. *Horm Res Paediatr*, 2013. 79(2):68-74.
13. Jaworski M, Wierzbicka E, Pludowski P, Szalecki M. Forearm bone density, cross-sectional size and muscle cross-sectional area in adolescents with diabetes mellitus type 1 assessed by peripheral quantitative computed tomography. *J Musculoskelet Neuronal Interact*, 2019. 19(4):435-447.
14. Janghorbani M, Feskanich D, Willett WC, Hu, F. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. *Diabetes Care*, 2006. 29(7):1573-8.
15. Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, Shepelkevich AP, Zhurava IV, Korolenko GG, Salko OB, Cairolì E, Beck-Peccoz P and Chiodini I. Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. *Diabetes Care*, 2013. 36(6):1635-40.
16. Vestergaard, P., Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. *Osteoporos Int*, 2007. 18(4):427-44.
17. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL, Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. *J Clin Endocrinol Metab*, 2006. 91(9):3404-10.
18. Yamamoto, M, Yamauchi, M, and Sugimoto, T, Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus. *PLoS One*, 2019. 14(9): doi: e0222571.
19. Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani, U, Majumdar S, Link, TM, High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab*, 2010. 95(11):5045-55.
20. Farr JN, Drake MT, Amin S, Melton III, LJ, McCready LJ, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. *J Bone Miner Res*, 2014. 29(4):787-95.
21. Napoli N, Strollo, R, Paladini A, Briganti SI, Pozzilli P, Epstein S. The alliance of mesenchymal stem cells, bone, and diabetes. *Int J Endocrinol*, 2014. 2014:690783.
22. Pacicca DM, Brown T, Watkins D, Kover K, Yan Y, Prideaux M, Bonewald L. Elevated glucose acts directly on osteocytes to increase sclerostin expression in diabetes. *Sci Rep*, 2019. 9(1):17353.
23. Ma L, Oei L, Jiang L, Estrada K, Chen HY, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. *Eur J Epidemiol*, 2012. 27(5):319-32.
24. Compston JE, Flahive J, Hooven FH, Anderson Jr. FA, Adachi JD, Boonen S, Chapurlat RD, Cooper C, Díez-Perez A, Greenspan SL, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Silverman S, Siris ES, Watts NB, GeHlbach SH and the GLOW Investigators. Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW). *Calcif Tissue Int*, 2014. 94(2):223-31.
25. Walsh JS, and Vilaca T, Obesity, Type 2 Diabetes and Bone in Adults. *Calcif Tissue Int*, 2017. 100(5):528-535.
26. Maure MS, Burcham J, and Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. *J Gerontol A Biol Sci Med Sci*, 2005. 60(9):1157-62.
27. Zhu ZN, Jiang YF, Ding T, Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. *Bone*, 2014. 68:115-23.
28. Lecka-Czernik B, Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. *Curr Osteoporos Rep*, 2010. 8(4):178-84.
29. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. *J Clin Endocrinol Metab*, 2016. 101(1):157-66.

p 10-14 Bone Fragility Fracture Cont'd

30. Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. *J Clin Endocrinol Metab*, 2016. 101(1):44-51.
31. Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. *Diabetes Care*, 2018. 41(8):1809-1816.
32. Ye Y, Zhao CH, Liang J, Yang YQ, Yu MX, Qu XH. Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. *Front Pharmacol*, 2018. 9:1517.
33. Ljunggren Ö, Bolinder J, Johansson L, Wilding J, Langkilde A, Sjostrom D, Sugg J, Parikh, S. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. *Diabetes Obes Metab*, 2012. 14(11):990-9.
34. Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. *Diabetologia*, 2019. 62(10):1854-1867.
35. Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, Schreiner PJ, Margolis KL, Cauley JA, Nevitt MC, Black DM, Cummings SR. Older women with diabetes have a higher risk of falls: a prospective study. *Diabetes Care*, 2002. 25(10):1749-54.
36. Yang YQ, Zhao CH, Liang J, Yu MX, Qu XH. Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms. *Front Pharmacol*, 2017. 8:487.
37. Montes Castillo MC, Martínez Ramírez MJ, Soriano Arroyo R, Prieto Gomez I, Segarra Robles AB, Garrido-Martínez M, Santiago-Fernández P, Delgado Rodríguez M. Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women. *Sci Rep*, 2019. 9(1):13651.
38. Yang J, Huang C, Wu SS, Xu Y, Cai T, Chai SB, Yang ZR, Sun F, Zhan SY. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. *PLoS One*, 2017. 12(12): doi: e0187537.
39. Cheng L, Hu Y, Li YY, Cao X, Bai N, Lu TT, Li GQ, Li N, Wang AN, Mao XM. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. *Diabetes Metab Res Rev*, 2019. 35(7): doi: e3168.
40. Hygum K, Harsløf T, Jørgensen NR, Rungby J, Pedersen SB, Langdahla BL. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial. *Bone*, 2020. 132:115197.
41. Matteo M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, Marchionni N, Rotella CM, Mannucci E. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. *Diabetes Care*, 2008. 31(2):199-203.
42. Palermo A, D'Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. *Osteoporos Int*, 2015. 26(8):2073-89.
43. Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. *Diabetologia*, 2015. 58(10):2238-46.
44. Martinez-Laguna D, Nogues X, Abrahamsen B, Reyes C, Carbonell-Abella C, Diez-Perez A, Prieto-Alhambra D. Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study. *Osteoporos Int*, 2017. 28(9):2573-2581.
45. Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. *Eur J Endocrinol*, 2017. 176(3):R137-r157.

p 10-14 Bone Fragility Fracture Cont'd

46. Keegan T, Schwartz A, Bauer D, Sellmeyer D, Kelsey J. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. *Diabetes Care*, 2004. 27(7):1547-53.
47. Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. *J Bone Miner Res*, 2008. 23(1):112-20.
48. Schwartz AV, Pavo I, Alam J, Disch DP, Schuster D, Harris JM, Krege JH Teriparatide in patients with osteoporosis and type 2 diabetes. *Bone*, 2016. 91:152-8.
49. Ferrari, S., et al., Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. *Bone*, 2020. 134:115268.
50. Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? *Calcif Tissue Int*, 2011. 88(3):209-14.

p 16-19 Complementary Medicines – what you need to ask and how

1. Australian Institute of Health and Welfare. 2019 Diabetes Overview
<https://www.aihw.gov.au/reports-data/health-conditions-disability-deaths/diabetes>
2. Yeh G, Eisenberg D, Kapchuk T, Phillips R. Systematic review of herbs and dietary supplements for glycaemic control in diabetes. *Diabetes care*, 26 (4):1227-1294.
3. Dunning T. Overview of complementary and alternative medicine and diabetes. *Practical Diabetes*. 2014 31 (4):381-385.
4. Von Conrady, DM & Bonney, A. Patterns of complementary and alternative medicine use and health literacy in general practice patients in urban and regional Australia. *Australian Family Physician*. 2017 10 (5) <http://www.racgp.org.au/afp/2017/may>
5. Chang Hsiao-Yun, Wallis M, Tiralongo E. Use of complementary and alternative medicine among people living with diabetes: literature review. *Journal of Advanced Nursing* 2007 58 (4):307-318 doi: 10.1111/j.1365-2648.2007.04291.x
6. Manya K, Champion B, Dunning T. The use of complementary and alternative medicine among people living with diabetes in Sydney. *BMC Complementary and Alternative Medicine*. 2012.;12: 2 doi: 10.1186/1472-6882-12-2
7. Dunning T, CAM Complementary and Alternative Medicine. *Australian Diabetes Educator*. 2012 Australian Diabetes Educators Association, Canberra.
8. Running A, Straffier-Grant J, Andrews W. A Survey of Hospice Use of Complementary Therapy. *Journal Hospice and Palliative Nursing*. 2005 10 (5):294-312.
9. Tilden V, Drach L, Tolle S. Complementary and alternative therapy use at end of life in community settings. *Journal of alternative and Complementary Medicine*. 2004 10 (5):811-817.
10. Australian Government National Health and Medical Research Council. Talking with your patients about complementary medicine – a resource for clinicians. April 2014
<https://www.nhmrc.gov.au/about-us/publications/talking-your-patients-about-complementary-medicine-resource-clinicians>
11. Pirotta M, Cohen M, Kotsirilos V, Farish J. Complementary therapies: have they become accepted in general practice? *Medical Journal Australia*. 2000 172 (3): 105-109.
12. Australian Medical Association. Position statement on complementary medicine.
<https://ama.com.au/position-statement/ama-position-statement-complementary-medicine-2018>
13. American Cancer Society. How do I talk to my doctor about alternative and complementary methods? 2015 <https://www.cancer.org/treatment/treatments-and-side-effects/complementary-and-alternative-medicine/complementary-and-alternative-methods-and-cancer/talking-to-doctor-about-cam.html>
14. Australian Department of Health and Ageing. National Strategy for Quality use of Medicine. 2002 Canberra Accessed 21 April 2020
<https://www1.health.gov.au/internet/main/publishing.nsf/Content/nmp-quality.htm>

p 16-19 Complementary Medicines Cont'd

15. Singh Ospina, N, Phillips, KA, Rodriguez-Gutierrez, R, Castaneda-Guarderas A, Gionfriddo, MR; Branda, ME & Montori, VM. Eliciting the Patient's Agenda- Secondary Analysis of Recorded Clinical Encounters. *J GEN INTERN MED* 34, 36–40 (2019). <https://doi.org/10.1007/s11606-018-4540-5>
16. Ward B. How to Improve Patient Hand-Offs. *Health Leaders*. 13 March 2012 <https://www.healthleadersmedia.com/nursing/how-improve-patient-handoffs>
17. Braun L Cohen M. *Herbs and Natural Supplements: an Evidence-Based Approach*. 2012 Sydney, Elsevier.
18. Peters D, Cohen M. *New Medicine: How to Integrate Complementary and Conventional Medicine for the Safest and Most Effective Treatment*, 2005. Dorling Kindesley Limited, Melbourne.

p 20-24 Haemochromatosis & diabetes

1. Utzschneider KM, and Kowdley KV. Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. *Nature Reviews Endocrinology*. 2010;6(1):26.
2. Fernandez-Real J-M, Vendrell J, Baiget M, Gimferrer E, and Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. *Diabetes care*. 1999;22(3):525.
3. Piperno A, Bertola F, and Bentivegna A. *Juvenile Hemochromatosis*. 2020.
4. Kowdley KV, Brown KE, Ahn J, and Sundaram V. ACG Clinical Guideline: Hereditary Hemochromatosis. *American Journal of Gastroenterology*. 2019;114(8):1202-18.
5. Hanson EH, Imperatore G, and Burke W. HFE Gene and Hereditary Hemochromatosis: A HuGE Review. *American Journal of Epidemiology*. 2001;154(3):193-206.

p32 – p34 Food Stuff – Dietetic management of Gastroparesis

1. Camilleri M. Updates on Gastroparesis, 2018 viewed 14th February 2020, https://www.westernsydney.edu.au/gimotility/gi_disorders/Gastroparesis
2. Parrish CR & Pastors JG, *Nutritional Management of Gastroparesis in People with Diabetes*, *Diabetes Spectrum*, vol.20, no.4:231-234
3. Sadiya A. Nutritional therapy for the management of gastroparesis: clinical review, *Diab Met Syndrome & Obesity: Targets & Therapy*, no.5 2012:329-335.
4. Camilleri M, Parkman HP, Shafi MA; Abell TL, Gerson L. Clinical Guideline: Management of Gastroparesis, *Am J Gastroenterol*, 108(1) 2013:18-38.
5. Bouras EP & Scolapio JS. Gastric Motility Disorders, *J Clin Gastroenterol*, 38(7) 2004:549-557
6. Lehmann S, Ferrie S and Carey S. Nutritional Management in Patients with Chronic Gastrointestinal Motility Disorders: A Systematic Literature Review, *Nutr Clin Practice*, 10.1002/ncp.10273 2009.
7. Bern EM & O'Brien RF. "Is it an eating disorder, gastrointestinal disorder or both?", *Curr Opin Pediatr*, 25, 2013:463-470.
8. Satherley R, Higgs S, Howard RA. Disordered eating practices in gastrointestinal disorders, *Appetite*, 84, 2014:240-250.

-- ENDS --